A randomized, open-label, blank-controlled, multicenter trial for Polyinosinic-Polycytidylic Acid Injection in the treatment of novel coronavirus pneumonia (COVID-19)

INTERVENTION: experimental group:Polyinosinic‐Polycytidylic Acid Injection and conventional therapy;control group:conventional therapy; CONDITION: Novel Coronavirus Pneumonia (COVID‐19) PRIMARY OUTCOME: Time to Clinical recovery; SECONDARY OUTCOME: Virus negative time and negative rate;Time and rate of disappearance of main symptoms (fever, fatigue, cough);The time when the condition becomes worse (transfer to RICU);BRT;Blood biochemistry; INCLUSION CRITERIA: 1. Patients with confirmed new coronavirus‐infected pneumonia; 2. Above 18 years old (inclusive); 3. Voluntarily sign written informed consent.